Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy
BBA Advances · 2025 · 7 · 100151
DOI: 10.1016/j.bbadva.2025.100151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BBA Advances, 2025. Verfasst von Quan-En Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: uBriGene Biosciences, Inc., Germantown, MD, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Biological drugs with gene and cell therapy potentials, including natural or rationally created biomacromolecules, recombinant proteins/enzymes, gene-carrying DNA/RNA fragments, oncolytic viruses, plasmid and viral vectors or other gene delivering vehicles with specific therapeutic genes and gene manipulation tools, and genetically modified and reprogrammed human cells comprise a large fraction of drug development candidates in modern precision and regeneration medicine. These drugs have displayed unique capabilities in treating patients with previously incurable diseases. However, most of the drug preparations have complex multimolecular structures and require specific biomanufacturing systems and many other additional biological active materials for drug synthesis, cell expansion, and production enhancement. Thus, the final products would have to be subjected to sequential extensive purification processes to exclude impurities and to concentrate the drug products after manufacturing. The quality evaluation for each drug product is an individualized process and must be specifically designed and performed according to the characteristics of the drug and its manufacturing and purification methods. Some of the Quality Control (QC) assays may be very costly and time-consuming, frequently with inconsistent test results from batch-to-batch. This review focuses on QC assessment strategy development for common gene and cell therapy drugs which use prokaryotic or eukaryotic cells for manufacturing or cell factories for in vitro expansions, especially for drug identification and concentration determination, impurity detection and quantification, drug potency, stability, and safety evaluations; and discusses some key issues for drug quality assessments in different categories and emphasizes the importance of individualized QC strategy design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- uBriGene Biosciences, Inc., Germantown, MD, USA.
- Forecyte Biosciences, Inc., Frederick, MD, USA.
- WZ Biosciences Inc., Rockville, MD, USA.
- Vigene Biosciences, Inc., Rockville, MD, USA.
Zitieren
APA
Yang, Q. E., Lee, N., Johnson, N., Hong, J., Zhao, J. Q., Sun, X., & Zhang, J. (2025). Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy. BBA Advances, 7, 100151. https://doi.org/10.1016/j.bbadva.2025.100151
Vancouver
Yang QE, Lee N, Johnson N, Hong J, Zhao JQ, Sun X, et al. Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy. BBA Advances. 2025;7:100151. doi:10.1016/j.bbadva.2025.100151
BibTeX
@article{Yang2025,
author = {Yang, Quan-En and Lee, Nicole and Johnson, Nicole and Hong, Jennifer and Zhao, Jenny Qinghua and Sun, Xiulian and Zhang, Jian},
title = {Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy},
journal = {BBA Advances},
year = {2025},
volume = {7},
pages = {100151},
doi = {10.1016/j.bbadva.2025.100151}
}
EUVIMED